• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Scandion Oncology

Less than 1K followers
All
Webcasts
Press releases
3rd party
ShowingAll content types

Regulatory press release25.06.2025, 17.00

Delisting of the shares of Scandion Oncology - last day of trading July 11, 2025

Scandion Oncology
Regulatory press release25.06.2025, 14.00

Scandion Oncology has applied for delisting of the company's shares from Nasdaq First North Growth Market

Scandion Oncology
Regulatory press release27.03.2025, 16.00

Scandion Oncology Announces Results of Annual General Meeting

Scandion Oncology

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release12.03.2025, 13.10

Scandion Oncology – Notice convening the Annual General Meeting

Scandion Oncology
Regulatory press release12.03.2025, 13.05

Scandion Oncology - Annual Report 2024

Scandion Oncology
Regulatory press release12.03.2025, 13.00

Scandion Oncology – Q4 & yearend report 2024

Scandion Oncology
Regulatory press release26.02.2025, 18.40

Scandion Oncology CEO Francois Martelet, MD will take over CMO tasks

Scandion Oncology
Regulatory press release26.02.2025, 18.35

Scandion Oncology announces rescheduled publication date for Q4 and Year-end 2024 report

Scandion Oncology
Regulatory press release26.02.2025, 18.30

Scandion Oncology’s Board of Directors emphasize need to find a partner before the Annual General Meeting

Scandion Oncology
Regulatory press release13.01.2025, 07.00

Scandion Oncology announces final data from the CORIST trial and is ready to move into a randomized phase II Proof of Concept trial in Colorectal Cancer

Scandion Oncology
Regulatory press release20.11.2024, 17.30

Warrants of series TO 2 were exercised to approximately 2.0 per cent and Scandion Oncology receives approximately SEK 0.3 million

Scandion Oncology
Regulatory press release14.11.2024, 08.30

Last day of trading in warrants of series TO 2 in Scandion Oncology is today, 14 November 2024

Scandion Oncology
Press release12.11.2024, 17.54

Redeye: Scandion Oncology Q3 2024 - Searching for a partner

Scandion Oncology
Scandion Oncology, Audiocast with teleconference, Q3'24
Webcast11.11.2024, 09.00

Scandion Oncology, Audiocast with teleconference, Q3'24

Scandion Oncology
Regulatory press release11.11.2024, 07.00

Scandion Oncology – Interim Report Q3 2024

Scandion Oncology
Press release05.11.2024, 17.00

Invitation to Scandion Oncology webcast and conference call November 11, 2024

Scandion Oncology
Regulatory press release04.11.2024, 08.30

Scandion Oncology announces the start of the exercise period for warrants of series TO 2

Scandion Oncology
Regulatory press release31.10.2024, 08.30

Correction: Scandion Oncology announces exercise price for warrants of series TO 2

Scandion Oncology
Regulatory press release30.10.2024, 17.00

Scandion Oncology announces exercise price for warrants of series TO 2

Scandion Oncology
Press release29.08.2024, 12.26

Redeye: Scandion Oncology Q2 2024 - Partnership represents best hope

Scandion Oncology